Cancer Statistics, 2021

Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal, Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal

Abstract

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2017) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2018) were collected by the National Center for Health Statistics. In 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States. After increasing for most of the 20th century, the cancer death rate has fallen continuously from its peak in 1991 through 2018, for a total decline of 31%, because of reductions in smoking and improvements in early detection and treatment. This translates to 3.2 million fewer cancer deaths than would have occurred if peak rates had persisted. Long-term declines in mortality for the 4 leading cancers have halted for prostate cancer and slowed for breast and colorectal cancers, but accelerated for lung cancer, which accounted for almost one-half of the total mortality decline from 2014 to 2018. The pace of the annual decline in lung cancer mortality doubled from 3.1% during 2009 through 2013 to 5.5% during 2014 through 2018 in men, from 1.8% to 4.4% in women, and from 2.4% to 5% overall. This trend coincides with steady declines in incidence (2.2%-2.3%) but rapid gains in survival specifically for nonsmall cell lung cancer (NSCLC). For example, NSCLC 2-year relative survival increased from 34% for persons diagnosed during 2009 through 2010 to 42% during 2015 through 2016, including absolute increases of 5% to 6% for every stage of diagnosis; survival for small cell lung cancer remained at 14% to 15%. Improved treatment accelerated progress against lung cancer and drove a record drop in overall cancer mortality, despite slowing momentum for other common cancers.

Keywords: cancer cases; cancer statistics; death rates; incidence; mortality.

© 2021 American Cancer Society.

References

    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 9 Regs Research Data with Delay-Adjustment, Malignant Only, Nov 2019 Sub (1975-2017) <Katrina/Rita Population Adjustment>-Linked To County Attributes-Total US, 1969-2018 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2020.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER Research Data, 9 Registries, Nov 2019 Sub (1975-2017)-Linked To County Attributes-Time Dependent (1990-2017) Income/Rurality, 1969-2018 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2020.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2019 Submission (2000-2017) <Katrina/Rita Population Adjustment>-Linked To County Attributes-Total US, 1969-2018 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2020.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 21 Regs Limited-Field Research Data + Hurricane Katrina Impacted Louisiana Cases with Delay-Adjustment, Malignant Only, Nov 2019 Sub (2000-2017) <Katrina/Rita Population Adjustment>-Linked To County Attributes-Total US, 1969-2018 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2020.
    1. Statistical Research and Applications Branch, National Cancer Institute. DevCan: Probability of Developing or Dying of Cancer Software. Version 6.7.8. Surveillance Research Program, Statistical Methodology and Applications, National Cancer Institute; 2020.
    1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2017. National Cancer Institute; 2020.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence Data-Cancer in North America (CiNA) Analytic File, 1995-2017, for Expanded Races, Custom File With County, American Cancer Society (ACS) Facts and Figures Projection Project (Which Includes Data From the Centers for Disease Control and Prevention's [CDC's] National Program of Cancer Registries [NPCR], Canadian Council of Cancer Registries' [CCCR's] Provincial and Territorial Registries, and the National Cancer Institute's [NCI's] SEER Registries). NAACCR; 2020.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence Data-Cancer in North America (CiNA) Analytic File, 1995-2017, for NHIAv2 Origin, Custom File With County, American Cancer Society (ACS) Facts and Figures Projection Project (Which Includes Data From the Centers for Disease Control and Prevention's [CDC's] National Program of Cancer Registries [NPCR], Canadian Council of Cancer Registries' [CCCR's] Provincial and Territorial Registries, and the National Cancer Institute's [NCI's] SEER Registries). NAACCR; 2020.
    1. Sherman R, Firth R, Charlton M, et al, eds. Cancer in North America: 2013-2017. Volume 1. Combined Cancer Incidence for the United States, Canada and North America. North American Association of Central Cancer Registries, Inc; 2020.
    1. Sherman R, Firth R, Charlton M, et al, eds. Cancer in North America: 2013-2017. Volume 2. Registry-Specific Cancer Incidence in the United States and Canada. North American Association of Central Cancer Registries, Inc; 2020.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Mortality-All COD, Total US (1969-2018) <Katrina/Rita Population Adjustment>-Linked To County Attributes-Total US, 1969-2018 Counties. National Cancer Institute, Division of Cancer Control and Prevention, Surveillance Research Program, Surveillance Systems Branch; 2020; underlying mortality data provided by the National Center for Health Statistics, 2020.
    1. Wingo PA, Cardinez CJ, Landis SH, et al. Long-term trends in cancer mortality in the United States, 1930-1998. Cancer. 2003;97(12 suppl):3133-3275.
    1. Murphy SL, Kochanek KD, Xu J, Heron M. Deaths: Final Data for 2012. National Vital Statistics Reports. Vol 63, No 9. National Center for Health Statistics; 2015.
    1. Sherman R, Firth R, Charlton M, et al, eds. Cancer in North America: 2013-2017. Volume 3: Registry-Specific Cancer Mortality in the United States and Canada. North American Association of Central Cancer Registries, Inc; 2020.
    1. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, third edition. Cancer. 2005;103:1457-1467.
    1. Fritz A, Percy C, Jack A, et al, eds. International Classification of Diseases for Oncology. 3rd ed. World Health Organization; 2000.
    1. World Health Organization. International Statistical Classification of Diseases and Related Health Problems. 10th Rev. Vols. I-III. World Health Organization; 2011.
    1. Surveillance Research Program, National Cancer Institute. SEER*Stat Software. Version 8.3.8. Surveillance Research Program, National Cancer Institute; 2020.
    1. Statistical Research and Applications Branch, National Cancer Institute, Joinpoint Regression Program. Version 4.8.0.1. Statistical Research and Applications Branch, National Cancer Institute; 2020.
    1. Clegg LX, Feuer EJ, Midthune DN, Fay MP, Hankey BF. Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst. 2002;94:1537-1545.
    1. Pickle LW, Hao Y, Jemal A, et al. A new method of estimating United States and state-level cancer incidence counts for the current calendar year. CA Cancer J Clin. 2007;57:30-42.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Populations-Total US (1969-2018) <Katrina/Rita Adjustment>-Linked To County Attributes-Total US, 1969-2018 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2019.
    1. DeSantis CE, Miller KD, Dale W, et al. Cancer statistics for adults aged 85 years and older, 2019. CA Cancer J Clin. 2019;69:452-467.
    1. Williams LA, Richardson M, Marcotte EL, Poynter JN, Spector LG. Sex ratio among childhood cancers by single year of age. Pediatr Blood Cancer. 2019;66:e27620.
    1. Ward EM, Sherman RL, Henley SJ, et al. Annual Report to the Nation on the Status of Cancer, 1999-2015, featuring cancer in men and women age 20-49 years. J Natl Cancer Inst. 2019;111:1279-1297.
    1. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626-638.
    1. Islami F, Goding Sauer A, Miller KD, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable factors in the United States in 2014. CA Cancer J Clin. 2018;68:31-54.
    1. Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med. 2013;368:351-364.
    1. Jeon J, Holford TR, Levy DT, et al. Smoking and lung cancer mortality in the United States from 2015 to 2065: a comparative modeling approach. Ann Intern Med. 2018;169:684-693.
    1. Siegel DA, Fedewa SA, Henley J, Pollack LA, Jemal A. Proportion of never smokers among men and women with lung cancer in seven U.S. states: a population-based cancer registry study. JAMA Oncol. Published online December 3, 2020.
    1. Redfield RR, Hahn SM, Sharpless NE. Redoubling efforts to help Americans quit smoking-federal initiatives to tackle the country's longest-running epidemic. N Engl J Med. 2020;383:1606-1609.
    1. U.S. Department of Health and Human Services. Smoking Cessation. A Report of the Surgeon General. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2020.
    1. Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med. 2013;368:341-350.
    1. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548-552.
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7-30.
    1. Moyer VA, U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120-134.
    1. Shoag JE, Nyame YA, Gulati R, Etzioni R, Hu JC. Reconsidering the trade-offs of prostate cancer screening. N Engl J Med. 2020;382:2465-2468.
    1. Negoita S, Feuer EJ, Mariotto A, et al. Annual Report to the Nation on the Status of Cancer, part II: recent changes in prostate cancer trends and disease characteristics. Cancer. 2018;124:2801-2814.
    1. Dalela D, Sun M, Diaz M, et al. Contemporary trends in the incidence of metastatic prostate cancer among US men: results from nationwide analyses. Eur Urol Focus. 2019;5:77-80.
    1. Jemal A, Culp MB, Ma J, Islami F, Fedewa SA. Prostate cancer incidence 5 years after U.S. Preventive Services Task Force recommendations against screening. J Natl Cancer Inst. Published online May 20, 2020. doi:10.1093/jnci/djaa068
    1. Krist A. U.S. Preventive Services Task Force: Draft Prostate Cancer Screening Recommendation, April 2017. Accessed November 19, 2020.
    1. Fenton JJ, Weyrick MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis, No. 154. AHRQ Report No. 17-05229-EF-1. Agency for Healthcare Research and Quality (AHRQ); 2018.
    1. U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. JAMA. 2018;319:1901-1913.
    1. Auvinen A, Rannikko A, Taari K, et al. A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale. Eur J Epidemiol. 2017;32:521-527.
    1. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378:1767-1777.
    1. Henley SJ, Ward EM, Scott S, et al. Annual Report to the Nation on the Status of Cancer, part I: national cancer statistics. Cancer. 2020;126:2225-2249.
    1. Pfeiffer RM, Webb-Vargas Y, Wheeler W, Gail MH. Proportion of U.S. trends in breast cancer incidence attributable to long-term changes in risk factor distributions. Cancer Epidemiol Biomarkers Prev. 2018;27:1214-1222.
    1. Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International patterns and trends in endometrial cancer incidence, 1978-2013. J Natl Cancer Inst. 2018;110:354-361.
    1. Clarke MA, Devesa SS, Harvey SV, Wentzensen N. Hysterectomy-corrected uterine corpus cancer incidence trends and differences in relative survival reveal racial disparities and rising rates of nonendometrioid cancers. J Clin Oncol. 2019;37:1895-1908.
    1. Morris LG, Tuttle RM, Davies L. Changing trends in the incidence of thyroid cancer in the United States. JAMA Otolaryngol Head Neck Surg. 2016;142:709-711.
    1. Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2:1023-1029.
    1. Harris JE. Cigarette smoking among successive birth cohorts of men and women in the United States during 1900-80. J Natl Cancer Inst. 1983;71:473-479.
    1. Jemal A, Ma J, Rosenberg PS, Siegel R, Anderson WF. Increasing lung cancer death rates among young women in southern and midwestern states. J Clin Oncol. 2012;30:2739-2744.
    1. Jemal A, Miller KD, Ma J, et al. Higher lung cancer incidence in young women than young men in the United States. N Engl J Med. 2018;378:1999-2009.
    1. Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70:145-164.
    1. Thrift AP, Gudenkauf FJ. Melanoma incidence among non-Hispanic Whites in all 50 US states from 2001 through 2015. J Natl Cancer Inst. 2020;112:533-539.
    1. Edlin BR, Eckhardt BJ, Shu MA, Holmberg SD, Swan T. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology. 2015;62:1353-1363.
    1. Pawlotsky JM. New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development. Semin Liver Dis. 2014;34:22-29.
    1. Division of Viral Hepatitis; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention; Centers for Disease Control and Prevention. Surveillance for Viral Hepatitis-United States, 2017. Accessed October 11, 2019.
    1. U.S. Preventive Services Task Force; Owens DK, Davidson KW, et al. Screening for hepatitis C virus infection in adolescents and adults: U.S. Preventive Services Task Force recommendation statement. JAMA. 2020;323:970-975.
    1. Chou R, Dana T, Fu R, et al. Screening for hepatitis C virus infection in adolescents and adults: updated evidence report and systematic review for the U.S. Preventive Services Task Force. JAMA. 2020;323:976-991.
    1. Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC recommendations for hepatitis C screening among adults-United States, 2020. MMWR Recomm Rep. 2020;69:1-17.
    1. Chow WH, Shuch B, Linehan WM, Devesa SS. Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics. Cancer. 2013;119:388-394.
    1. Jemal A, Ward EM, Johnson CJ, et al. Annual Report to the Nation on the Status of Cancer, 1975-2014, featuring survival. J Natl Cancer Inst. 2017;109:djx030.
    1. McAlpine JN, Temkin SM, Mackay HJ. Endometrial cancer: not your grandmother's cancer. Cancer. 2016;122:2787-2798.
    1. Fiorica JV. The role of topotecan in the treatment of advanced cervical cancer. Gynecol Oncol. 2003;90(3 pt 2):S16-S21.
    1. Sherman ME, Wang SS, Carreon J, Devesa SS. Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. Cancer. 2005;103:1258-1264.
    1. Croswell JM, Ransohoff DF, Kramer BS. Principles of cancer screening: lessons from history and study design issues. Semin Oncol. 2010;37:202-215.
    1. Sasaki K, Strom SS, O'Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2:e186-e193.
    1. National Lung Screening Trial Research Team; Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395-409.
    1. Pastorino U, Silva M, Sestini S, et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol. 2019;30:1162-1169.
    1. Huo J, Shen C, Volk RJ, Shih Y. Use of CT and chest radiography for lung cancer screening before and after publication of screening guidelines: intended and unintended uptake. JAMA Intern Med. 2017;177:439-441.
    1. Richards TB, Doria-Rose VP, Soman A, et al. Lung cancer screening inconsistent with U.S. Preventive Services Task Force recommendations. Am J Prev Med. 2019;56:66-73.
    1. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA. 2000;283:2975-2978.
    1. Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008;19:175-181.
    1. Tsodikov A, Gulati R, Heijnsdijk EAM, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med. 2017;167:449-455.
    1. National Cancer Institute, National Institutes of Health, Department of Health and Human Services. Cancer Trends Progress Report, 2020. Accessed October 7, 2020.
    1. American Cancer Society. Cancer Prevention & Early Detection Facts & Figures 2019-2020. American Cancer Society; 2019.
    1. Berk-Krauss J, Stein JA, Weber J, Polsky D, Geller AC. New systematic therapies and trends in cutaneous melanoma deaths among US Whites, 1986-2016. Am J Public Health. 2020;110:731-733.
    1. Howlader N, Forjaz G, Mooradian MJ, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383:640-649.
    1. Li Y, Appius A, Pattipaka T, Feyereislova A, Cassidy A, Ganti AK. Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA. PLoS One. 2019;14:e0209709.
    1. Minguet J, Smith KH, Bramlage P. Targeted therapies for treatment of non-small cell lung cancer-recent advances and future perspectives. Int J Cancer. 2016;138:2549-2561.
    1. Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35:3924-3933.
    1. Malhotra J, Jabbour SK, Aisner J. Current state of immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res. 2017;6:196-211.
    1. Rami-Porta R, Call S, Dooms C, et al. Lung cancer staging: a concise update. Eur Respir J. 2018;51:1800190.
    1. Jones GS, Baldwin DR. Recent advances in the management of lung cancer. Clin Med (Lond). 2018;18(suppl 2):s41-s46.
    1. Liu Y, Colditz GA, Kozower BD, et al. Association of Medicaid expansion under the Patient Protection and Affordable Care Act with non-small cell lung cancer survival. JAMA Oncol. 2020;6:1289-1290.
    1. Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013;105:175-201.
    1. Brouwer AF, Eisenberg MC, Meza R. Age Effects and temporal trends in HPV-related and HPV-unrelated oral cancer in the United States: a multistage carcinogenesis modeling analysis. PLoS One. 2016;11:e0151098.
    1. Heron M, Anderson RN. Changes in the leading cause of death: recent patterns in heart disease and cancer mortality. NCHS Data Brief. 2016;254:1-8.
    1. Siegel RL, Fedewa SA, Miller KD, et al. Cancer statistics for Hispanics/Latinos, 2015. CA Cancer J Clin. 2015;65:457-480.
    1. Torre LA, Sauer AM, Chen MS Jr, Kagawa-Singer M, Jemal A, Siegel RL. Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: converging incidence in males and females. CA Cancer J Clin. 2016;66:182-202.
    1. Islami F, Fedewa SA, Jemal A. Trends in cervical cancer incidence rates by age, race/ethnicity, histological subtype, and stage at diagnosis in the United States. Prev Med. 2019;123:316-323.
    1. Saslow D, Andrews KS, Manassaram-Baptiste D, Smith RA, Fontham ETH, American Cancer Society Guideline Development Group. Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation. CA Cancer J Clin. 2020;70:274-280.
    1. Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70:321-346.
    1. Goding Sauer A, Bandi P, Saslow D, Islami F, Jemal A, Fedewa SA. Geographic and sociodemographic differences in cervical cancer screening modalities. Prev Med. 2020;133:106014.
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7-34.
    1. Loke AY, Kwan ML, Wong YT, Wong AKY. The uptake of human papillomavirus vaccination and its associated factors among adolescents: a systematic review. J Prim Care Community Health. 2017;8:349-362.
    1. Elam-Evans LD, Yankey D, Singleton JA, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years-United States, 2019. MMWR Morb Mortal Wkly Rep. 2020;69:1109-1116.
    1. Smith A, Baines N, Mermon S, et al. Moving toward the elimination of cervical cancer: modelling the health and economic benefits of increasing uptake of human papillomavirus vaccines. Curr Oncol. 2019;26:80-84.
    1. Lei J, Ploner A, Elfstrom KM, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383:1340-1348.
    1. Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004;54:78-93.
    1. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of Blacks and Whites after a cancer diagnosis. JAMA. 2002;287:2106-2113.
    1. Bailey ZD, Krieger N, Agenor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389:1453-1463.
    1. Collin LJ, Gaglioti AH, Beyer KMM, et al. Neighborhood-level redlining and lending bias are associated with breast cancer mortality in a large and diverse metropolitan area. Cancer Epidemiol Biomarkers Prev. Published online October 2, 2020. doi:10.1158/1055-9965.EPI-20-1038
    1. Nelson DE, Mowery P, Asman K, et al. Long-term trends in adolescent and young adult smoking in the United States: metapatterns and implications. Am J Public Health. 2008;98:905-915.
    1. Centers for Disease Control and Prevention (CDC), Behavioral Risk Factor Surveillance System (BRFSS). 2018 BRFSS Survey Data and Documentation. Accessed September 27, 2019.
    1. Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases. 2008 through 2019 Adolescent Human Papillomavirus (HPV) Vaccination Coverage Trend Report. Accessed October 14, 2020.
    1. Nguyen BT, Han X, Jemal A, Drope J. Diet quality, risk factors and access to care among low-income uninsured American adults in states expanding Medicaid vs. states not expanding under the affordable care act. Prev Med. 2016;91:169-171.
    1. Sommers BD, Gawande AA, Baicker K. Health insurance coverage and health-what the recent evidence tells us. N Engl J Med. 2017;377:586-593.
    1. Kantarjian HM, Keating MJ, Freireich EJ. Toward the potential cure of leukemias in the next decade. Cancer. 2018;124:4301-4313.
    1. Schafer ES, Hunger SP. Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults. Nat Rev Clin Oncol. 2011;8:417-424.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj